24 results on '"Campana, D."'
Search Results
2. EUSO-SPB1 Mission and Science
- Author
-
Collaboration, JEM-EUSO, Abdellaoui, G., Abe, S., Adams. Jr., J. H., Allard, D., Alonso, G., Anchordoqui, L., Anzalone, A., Arnone, E., Asano, K., Attallah, R., Attoui, H., Pernas, M. Ave, Bachmann, R., Bacholle, S., Bagheri, M., Bakiri, M., Baláz, J., Barghini, D., Bartocci, S., Battisti, M., Bayer, J., Beldjilali, B., Belenguer, T., Belkhalfa, N., Bellotti, R., Belov, A. A., Benmessai, K., Bertaina, M., Bertone, P. F., Biermann, P. L., Bisconti, F., Blaksley, C., Blanc, N., Blin-Bondil, S., Bobik, P., Bogomilov, M., Bolmgren, K., Bozzo, E., Briz, S., Bruno, A., Caballero, K. S., Cafagna, F., Cambié, G., Campana, D., Capdevielle, J. N., Capel, F., Caramete, A., Caramete, L., Caruso, R., Casolino, M., Cassardo, C., Castellina, A., Catalano, O., Cellino, A., Černý, K., Chikawa, M., Chiritoi, G., Christl, M. J., Colalillo, R., Conti, L., Cotto, G., Crawford, H. J., Cremonini, R., Creusot, A., Cummings, A., Gónzalez, A. de Castro, de la Taille, C., del Peral, L., Desiato, J., Damian, A. Diaz, Diesing, R., Dinaucourt, P., Djakonow, A., Djemil, T., Ebersoldt, A., Ebisuzaki, T., Eser, J., Fenu, F., Fernández-González, S., Ferrarese, S., Filippatos, G., Finch, W., Fornaro, C., Fouka, M., Franceschi, A., Franchini, S., Fuglesang, C., Fujii, T., Fukushima, M., Galeotti, P., García-Ortega, E., Gardiol, D., Garipov, G. K., Gascón, E., Gazda, E., Genci, J., Golzio, A., Gorodetzky, P., Gregg, R., Green, A., Guarino, F., Guépin, C., Guzmán, A., Hachisu, Y., Haungs, A., Heigbes, T., Carretero, J. Hernández, Hulett, L., Ikeda, D., Inoue, N., Inoue, S., Isgrò, F., Itow, Y., Jammer, T., Jeong, S., Jochum, J., Joven, E., Judd, E. G., Jung, A., Kajino, F., Kajino, T., Kalli, S., Kaneko, I., Kasztelan, M., Katahira, K., Kawai, K., Kawasaki, Y., Kedadra, A., Khales, H., Khrenov, B. A., Kim, Jeong-Sook, Kim, Soon-Wook, Kleifges, M., Klimov, P. A., Kreykenbohm, I., Krizmanic, J. F., Królik, K., Kungel, V., Kurihara, Y., Kusenko, A., Kuznetsov, E., Lahmar, H., Lakhdari, F., Licandro, J., Campano, L. López, Martínez, F. López, Mackovjak, S., Mahdi, M., Mandát, D., Manfrin, M., Marcelli, L., Marcos, J. L., Marszał, W., Martín, Y., Martinez, O., Mase, K., Mastafa, M., Matthews, J. N., Mebarki, N., Medina-Tanco, G., Menshikov, A., Merino, A., Mese, M., Meseguer, J., Meyer, S. S., Mimouni, J., Miyamoto, H., Mizumoto, Y., Monaco, A., Ríos, J. A. Morales de los, Nachtman, J. M., Nagataki, S., Naitamor, S., Napolitano, T., Neronov, A., Nomoto, K., Nonaka, T., Ogawa, T., Ogio, S., Ohmori, H., Olinto, A. V., Onel, Y., Osteria, G., Otte, A. N., Pagliaro, A., Painter, W., Panasyuk, M. I., Panico, B., Parizot, E., Park, I. H., Pastircak, B., Paul, T., Pech, M., Pérez-Grande, I., Perfetto, F., Peter, T., Picozza, P., Pindado, S., Piotrowski, L. W., Piraino, S., Plebaniak, Z., Pollini, A., Popescu, E. M., Prevete, R., Prévôt, G., Prieto, H., Przybylak, M., Puehlhofer, G., Putis, M., Reardon, P., Reno, M. H., Reyes, M., Ricci, M., Frías, M. D. Rodríguez, Matamala, O. F. Romero, Ronga, F., Sabau, M. D., Saccá, G., Sagawa, H., Sahnoune, Z., Saito, A., Sakaki, N., Salazar, H., Sánchez, J. L., Balanzar, J. C. Sanchez, Santangelo, A., Sanz-Andrés, A., Saprykin, O. A., Sarazin, F., Sato, M., Scagliola, A., Schanz, T., Schieler, H., Schovánek, P., Scotti, V., Serra, M., Sharakin, S. A., Shimizu, H. M., Shinozaki, K., Soriano, J. F., Sotgiu, A., Stan, I., Strharský, I., Sugiyama, N., Supanitsky, D., Suzuki, M., Szabelski, J., Tajima, N., Tajima, T., Takahashi, Y., Takeda, M., Takizawa, Y., Talai, M. C., Tameda, Y., Tenzer, C., Thomas, S. B., Tibolla, O., Tkachev, L. G., Tomida, T., Tone, N., Toscano, S., Traïche, M., Tsunesada, Y., Tsuno, K., Turriziani, S., Uchihori, Y., Valdés-Galicia, J. F., Vallania, P., Valore, L., Vankova-Kirilova, G., Venters, T. M., Vigorito, C., Villaseñor, L., Vlcek, B., von Ballmoos, P., Vrabel, M., Wada, S., Watanabe, J., Watts. Jr., J., Muñoz, R. Weigand, Weindl, A., Wiencke, L., Wille, M., Wilms, J., Yamamoto, T., Yang, J., Yano, H., Yashin, I. V., Yonetoku, D., Yoshida, S., Young, R., Zgura, I. S., Zotov, M. Yu., and Marchi, A. Zuccaro
- Subjects
Astrophysics - Instrumentation and Methods for Astrophysics ,Astrophysics - High Energy Astrophysical Phenomena - Abstract
The Extreme Universe Space Observatory on a Super Pressure Balloon 1 (EUSO-SPB1) was launched in 2017 April from Wanaka, New Zealand. The plan of this mission of opportunity on a NASA super pressure balloon test flight was to circle the southern hemisphere. The primary scientific goal was to make the first observations of ultra-high-energy cosmic-ray extensive air showers (EASs) by looking down on the atmosphere with an ultraviolet (UV) fluorescence telescope from suborbital altitude (33~km). After 12~days and 4~hours aloft, the flight was terminated prematurely in the Pacific Ocean. Before the flight, the instrument was tested extensively in the West Desert of Utah, USA, with UV point sources and lasers. The test results indicated that the instrument had sensitivity to EASs of approximately 3 EeV. Simulations of the telescope system, telescope on time, and realized flight trajectory predicted an observation of about 1 event assuming clear sky conditions. The effects of high clouds were estimated to reduce this value by approximately a factor of 2. A manual search and a machine-learning-based search did not find any EAS signals in these data. Here we review the EUSO-SPB1 instrument and flight and the EAS search., Comment: 18 pages, 19 figures
- Published
- 2024
- Full Text
- View/download PDF
3. Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study
- Author
-
Albertelli, M., Rossi, G., Nazzari, E., Genova, C., Biello, F., Rijavec, E., Dal Bello, M. G., Patti, L., Tagliamento, M., Barletta, G., Morabito, P., Boschetti, M., Dotto, A., Campana, D., Ferone, D., and Grossi, F.
- Published
- 2024
- Full Text
- View/download PDF
4. Potential Effects of Physical Activity During Menopause According to a Computational Model of Bone Remodeling Applied to the Femur
- Author
-
Franco, F., Campana, D. M., Borau Zamora, C., Berli, M. E., Magjarević, Ratko, Series Editor, Ładyżyński, Piotr, Associate Editor, Ibrahim, Fatimah, Associate Editor, Lackovic, Igor, Associate Editor, Rock, Emilio Sacristan, Associate Editor, Lopez, Natalia M., editor, and Tello, Emanuel, editor
- Published
- 2024
- Full Text
- View/download PDF
5. EUSO-SPB1 mission and science
- Author
-
Abdellaoui, G., Abe, S., Adams, J.H., Jr., Allard, D., Alonso, G., Anchordoqui, L., Anzalone, A., Arnone, E., Asano, K., Attallah, R., Attoui, H., Pernas, M. Ave, Bachmann, R., Bacholle, S., Bagheri, M., Bakiri, M., Baláz, J., Barghini, D., Bartocci, S., Battisti, M., Bayer, J., Beldjilali, B., Belenguer, T., Belkhalfa, N., Bellotti, R., Belov, A.A., Benmessai, K., Bertaina, M., Bertone, P.F., Biermann, P.L., Bisconti, F., Blaksley, C., Blanc, N., Blin-Bondil, S., Bobik, P., Bogomilov, M., Bolmgren, K., Bozzo, E., Briz, S., Bruno, A., Caballero, K.S., Cafagna, F., Cambié, G., Campana, D., Capdevielle, J.N., Capel, F., Caramete, A., Caramete, L., Caruso, R., Casolino, M., Cassardo, C., Castellina, A., Catalano, O., Cellino, A., Černý, K., Chikawa, M., Chiritoi, G., Christl, M.J., Colalillo, R., Conti, L., Cotto, G., Crawford, H.J., Cremonini, R., Creusot, A., Cummings, A., de Castro Gónzalez, A., de la Taille, C., del Peral, L., Desiato, J., Damian, A. Diaz, Diesing, R., Dinaucourt, P., Djakonow, A., Djemil, T., Ebersoldt, A., Ebisuzaki, T., Eser, J., Fenu, F., Fernández-González, S., Ferrarese, S., Filippatos, G., Finch, W., Fornaro, C., Fouka, M., Franceschi, A., Franchini, S., Fuglesang, C., Fujii, T., Fukushima, M., Galeotti, P., García-Ortega, E., Gardiol, D., Garipov, G.K., Gascón, E., Gazda, E., Genci, J., Golzio, A., Gorodetzky, P., Gregg, R., Green, A., Guarino, F., Guépin, C., Guzmán, A., Hachisu, Y., Haungs, A., Heigbes, T., Carretero, J. Hernández, Hulett, L., Ikeda, D., Inoue, N., Inoue, S., Isgrò, F., Itow, Y., Jammer, T., Jeong, S., Jochum, J., Joven, E., Judd, E.G., Jung, A., Kajino, F., Kajino, T., Kalli, S., Kaneko, I., Kasztelan, M., Katahira, K., Kawai, K., Kawasaki, Y., Kedadra, A., Khales, H., Khrenov, B.A., Kim, Jeong-Sook, Kim, Soon-Wook, Kleifges, M., Klimov, P.A., Kreykenbohm, I., Krizmanic, J.F., Królik, K., Kungel, V., Kurihara, Y., Kusenko, A., Kuznetsov, E., Lahmar, H., Lakhdari, F., Licandro, J., Campano, L. López, Martínez, F. López, Mackovjak, S., Mahdi, M., Mandát, D., Manfrin, M., Marcelli, L., Marcos, J.L., Marszał, W., Martín, Y., Martinez, O., Mase, K., Mastafa, M., Matthews, J.N., Mebarki, N., Medina-Tanco, G., Menshikov, A., Merino, A., Mese, M., Meseguer, J., Meyer, S.S., Mimouni, J., Miyamoto, H., Mizumoto, Y., Monaco, A., de los Ríos, J.A. Morales, Nachtman, J.M., Nagataki, S., Naitamor, S., Napolitano, T., Neronov, A., Nomoto, K., Nonaka, T., Ogawa, T., Ogio, S., Ohmori, H., Olinto, A.V., Onel, Y., Osteria, G., Otte, A.N., Pagliaro, A., Painter, W., Panasyuk, M.I., Panico, B., Parizot, E., Park, I.H., Pastircak, B., Paul, T., Pech, M., Pérez-Grande, I., Perfetto, F., Peter, T., Picozza, P., Pindado, S., Piotrowski, L.W., Piraino, S., Plebaniak, Z., Pollini, A., Popescu, E.M., Prevete, R., Prévôt, G., Prieto, H., Przybylak, M., Puehlhofer, G., Putis, M., Reardon, P., Reno, M.H., Reyes, M., Ricci, M., Frías, M.D. Rodríguez, Matamala, O.F. Romero, Ronga, F., Sabau, M.D., Saccá, G., Sagawa, H., Sahnoune, Z., Saito, A., Sakaki, N., Salazar, H., Sánchez, J.L., Balanzar, J.C. Sanchez, Santangelo, A., Sanz-Andrés, A., Saprykin, O.A., Sarazin, F., Sato, M., Scagliola, A., Schanz, T., Schieler, H., Schovánek, P., Scotti, V., Serra, M., Sharakin, S.A., Shimizu, H.M., Shinozaki, K., Soriano, J.F., Sotgiu, A., Stan, I., Strharský, I., Sugiyama, N., Supanitsky, D., Suzuki, M., Szabelski, J., Tajima, N., Tajima, T., Takahashi, Y., Takeda, M., Takizawa, Y., Talai, M.C., Tameda, Y., Tenzer, C., Thomas, S.B., Tibolla, O., Tkachev, L.G., Tomida, T., Tone, N., Toscano, S., Traïche, M., Tsunesada, Y., Tsuno, K., Turriziani, S., Uchihori, Y., Valdés-Galicia, J.F., Vallania, P., Valore, L., Vankova-Kirilova, G., Venters, T.M., Vigorito, C., Villaseñor, L., Vlcek, B., von Ballmoos, P., Vrabel, M., Wada, S., Watanabe, J., Watts, J., Jr., Muñoz, R. Weigand, Weindl, A., Wiencke, L., Wille, M., Wilms, J., Yamamoto, T., Yang, J., Yano, H., Yashin, I.V., Yonetoku, D., Yoshida, S., Young, R., Zgura, I.S., Zotov, M.Yu., and Marchi, A. Zuccaro
- Published
- 2024
- Full Text
- View/download PDF
6. OC.06.3: ITANET NATIONAL PROSPECTIVE DATABASE: A COMPREHENSIVE ANALYSIS OF EPIDEMIOLOGY AND CLINICAL PRESENTATION OF GEP-NEN IN ITALY
- Author
-
Panzuto, F., primary, Partelli, S., additional, Campana, D., additional, Pusceddu, S., additional, Spada, F., additional, Cives, M., additional, Tafuto, S., additional, Bertuzzi, A., additional, Gelsomino, F., additional, Rinzivillo, M., additional, Marini, M., additional, and Falconi, M., additional
- Published
- 2024
- Full Text
- View/download PDF
7. Exploring tear viscosity with quartz crystal microbalance technology.
- Author
-
Muñoz, G., Millicovsky, M., Cerrudo, J., Peñalva, A., Machtey, M., Reta, J., Torres, R., Campana, D., and Zalazar, M.
- Abstract
Tear viscosity is a critical property affecting tear distribution and ocular surface stability. While not widely established as a primary diagnostic marker, deviations from normal viscosity can impact ocular health, potentially contributing to conditions such as dry eye syndrome. Despite their importance, traditional viscometers require sample volumes that are not feasible to use with tear volume. This research introduces a novel Quartz Crystal Microbalance (QCM)-based method for tear viscosity measurement, offering a viscometer prototype that operates with minimal sample volumes. Human tear samples, solutions used in artificial eye drops, and various commercial eye drop brands were evaluated. Results show that the QCM method aligns with established viscosity ranges. The average viscosity of healthy human tears was found to be 1.73 ± 0.61 cP, aligning with the typical range of 1–10 cP. Variability in the viscosities of eye drop can be attributed to differences in their chemical compositions. The QCM method offers benefits such as reduced sample consumption and rapid results, enhancing understanding of tear dynamics for ocular health. Further research with larger sample sizes is needed to establish normative viscosity values in healthy individuals and those with dry eye syndrome, which is crucial for validating the device's clinical efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Gamma-Ray Burst Observations by the High-Energy Particle Detector on board the China Seismo-Electromagnetic Satellite between 2019 and 2021.
- Author
-
Palma, F., Martucci, M., Neubüser, C., Sotgiu, A., Follega, F. M., Ubertini, P., Bazzano, A., Rodi, J. C., Ammendola, R., Badoni, D., Bartocci, S., Battiston, R., Beolè, S., Bertello, I., Burger, W. J., Campana, D., Cicone, A., Cipollone, P., Coli, S., and Conti, L.
- Subjects
PARTICLE detectors ,PARTICLE board ,GAMMA ray bursts ,PHOTON flux ,MONTE Carlo method ,COSMIC rays - Abstract
In this paper we report the detection of five strong gamma-ray bursts (GRBs) by the High-Energy Particle Detector (HEPD-01) mounted on board the China Seismo-Electromagnetic Satellite, operational since 2018 on a Sun-synchronous polar orbit at a ∼507 km altitude and 97° inclination. HEPD-01 was designed to detect high-energy electrons in the energy range 3–100 MeV, protons in the range 30–300 MeV, and light nuclei in the range 30–300 MeV n
−1 . Nonetheless, Monte Carlo simulations have shown HEPD-01 is sensitive to gamma-ray photons in the energy range 300 keV–50 MeV, even if with a moderate effective area above ∼5 MeV. A dedicated time correlation analysis between GRBs reported in literature and signals from a set of HEPD-01 trigger configuration masks has confirmed the anticipated detector sensitivity to high-energy photons. A comparison between the simultaneous time profiles of HEPD-01 electron fluxes and photons from GRB190114C, GRB190305A, GRB190928A, GRB200826B, and GRB211211A has shown a remarkable similarity, in spite of the different energy ranges. The high-energy response, with peak sensitivity at about 2 MeV, and moderate effective area of the detector in the actual flight configuration explain why these five GRBs, characterized by a fluence above ∼3 × 10−5 erg cm−2 in the energy interval 300 keV–50 MeV, have been detected. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
9. A rapidly growing ulcer: an atypical presentation of Merkel cell carcinoma.
- Author
-
Clarizio G, Merli Y, Campana D, Corti B, Agostinelli C, and Pileri A
- Published
- 2024
- Full Text
- View/download PDF
10. Fratricide-resistant CD7-CAR T cells in T-ALL.
- Author
-
Oh BLZ, Shimasaki N, Coustan-Smith E, Chan E, Poon L, Lee SHR, Yeap F, Tan LK, Chai LYA, Le Bert N, Tan N, Bertoletti A, Chen SP, Del Bufalo F, Becilli M, Locatelli F, Yeoh AEJ, and Campana D
- Abstract
T cell acute lymphoblastic leukemia (T-ALL) is difficult to treat when it relapses after therapy or is chemoresistant; the prognosis of patients with relapsed or refractory T-ALL is generally poor. We report a case series of 17 such patients who received autologous chimeric antigen receptor (CAR) T cells expressing an anti-CD7 CAR and an anti-CD7 protein expression blocker (PEBL), which prevented CAR T cell fratricide. Despite high leukemic burden and low CAR T cell dosing, 16 of the 17 patients attained minimal residual disease-negative complete remission within 1 month. The remaining patient had CD7
- T-ALL cells before infusion, which persisted after infusion. Toxicities were mild: cytokine release syndrome grade 1 in ten patients and grade 2 in three patients; immune effector cell-associated neurotoxicity syndrome grade 1 in two patients. Eleven patients remained relapse-free (median follow-up, 15 months), including all nine patients who received an allotransplant. The first patient is in remission 55 months after infusion without further chemotherapy or transplantation; circulating CAR T cells were detectable for 2 years. T cells regenerating after lymphodepletion lacked CD7 expression, were polyclonal and responded to SARS-CoV-2 vaccination; CD7+ immune cells reemerged concomitantly with CAR T cell disappearance. In conclusion, autologous anti-CD7 PEBL-CAR T cells have powerful antileukemic activity and are potentially an effective option for the treatment of T-ALL., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)- Published
- 2024
- Full Text
- View/download PDF
11. Lutetium [ 177 Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study.
- Author
-
Lastoria S, Rodari M, Sansovini M, Baldari S, D'Agostini A, Cervino AR, Filice A, Salgarello M, Perotti G, Nieri A, Campana D, Pellerito RE, Pomposelli E, Gaudieri V, Storto G, Grana CM, Signore A, Boni G, Dondi F, Simontacchi G, and Seregni E
- Subjects
- Humans, Male, Female, Italy, Middle Aged, Prospective Studies, Aged, Organometallic Compounds therapeutic use, Adult, Lutetium therapeutic use, Quality of Life, Radiopharmaceuticals therapeutic use, Neuroendocrine Tumors radiotherapy, Neuroendocrine Tumors pathology, Pancreatic Neoplasms radiotherapy, Stomach Neoplasms radiotherapy, Octreotide analogs & derivatives, Octreotide therapeutic use, Intestinal Neoplasms radiotherapy
- Abstract
Purpose: Gastroenteropancreatic -neuroendocrine tumours (GEP-NETs) are commonly treated with surgical resection or long-term therapies for tumour growth control. Lutetium [
177 Lu]-DOTA-TATE was approved for the treatment of GEP-NETs after the phase III NETTER 1trial demonstrated improved progression free survival, objective response rates and health-related quality of life (HRQoL) compared to high-dose somatostatin analogues. No real-world data exist on prescribing habits and clinically significant endpoints for [177 Lu]Lu-DOTA-TATE treatment in Italy. REAL-LU is a multicentre, long-term observational study in patients with unresectable/metastatic GEP-NETs progressing on standard therapies in Italian clinical practice. A pre-specified interim analysis was performed at the end of the enrolment period, data from which are described herein., Methods: Overall duration of REAL-LU will be approximately 48 months, with 12- and 36-month recruitment and follow-up periods, respectively. The primary objective is to evaluate [177 Lu]Lu-DOTA-TATE effectiveness in terms of progression-free survival. Secondary objectives include safety, impact on HRQoL, and identification of prognostic factors. This pre-specified interim analysis describes patient profiles, at the end of enrollment, of those prescribed [177 Lu]Lu-DOTA-TATE for GEP-NETs in Italy., Results: Among 161 evaluable patients, mean age was 64.7 ± 10.3 years at study entry, 83.8% presented with no clinical signs of disease at physical examination, and most had minor disease symptoms. All patients had metastatic disease, most commonly in the liver (83.9%) with a median of two metastatic sites. In 90.7% of patients, the disease was stage IV, and 68.3% had ≥ 1 target lesion. [177 Lu]Lu-DOTA-TATE was prescribed mainly as second-line therapy (61.6%) and following surgery (58.4%). HRQoL assessments revealed high levels of functioning and low levels of symptoms at baseline; 50.0% of patients were symptom-free at study entry., Conclusion: The characteristics of patients who received [177Lu]Lu-DOTA-TATE in Italy are similar to those of the GEP-NET population of NETTER 1 with trial but with a higher proportion of patients with a grade 2 (71%). With regard to the tumor grade profile, our study cohort appears to be closer to that of NETTER-2 study population which included patients with G2 or G3 advanced GEP-NETs (i.e. Ki-67 ≥ 10% and ≤ 55%). Further analysis of effectiveness and safety can be anticipated as REAL-LU data mature., Study Registration: ClinicalTrials.gov, NCT04727723; Study Registration Date: 25 January, 2021; https://clinicaltrials.gov/study/NCT04727723?cond=NCT04727723&rank=1., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
12. Gastrointestinal side effects of somatostatin analogs in neuroendocrine tumors: a focused review.
- Author
-
Marasco M, Dell'Unto E, Laviano A, Campana D, and Panzuto F
- Subjects
- Humans, Gastrointestinal Diseases chemically induced, Diarrhea chemically induced, Abdominal Pain etiology, Abdominal Pain chemically induced, Constipation chemically induced, Octreotide adverse effects, Octreotide therapeutic use, Neuroendocrine Tumors drug therapy, Somatostatin analogs & derivatives, Somatostatin adverse effects, Quality of Life
- Abstract
Neuroendocrine tumors (NETs) are a group of well-differentiated heterogeneous neoplasms characterized by slow progression and distinct clinical and biological behavior. In the majority of patients with NET, first-line treatment is represented by somatostatin analogs (SSAs) that, despite being drugs with high tolerability (even at high doses) and providing to carcinoid symptoms control and anti-proliferative effects, may present some side effects, with potential impact on quality of life and nutritional status. The most frequent side effects are represented by gastrointestinal events in particular alterations in bowel habits (diarrhea and constipation), abdominal pain, exocrine pancreatic insufficiency, and cholelithiasis. Considering the relative rarity of NETs, literature about frequency and standard clinical management of adverse events SSA-related is still lacking and heterogeneous. The aim of this review is to arm gastroenterologists and other physicians treating NET patients with essential knowledge on the side effects of SSAs. By identifying and managing these adverse events early, healthcare professionals can offer optimal care, avert foreseeable complications, and ensure the best outcomes for patients. Without such early recognition, there is a risk of diminishing the patient's quality of life and their ability to sustain treatment over time., (© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
13. Challenges and future perspectives for the use of temozolomide in the treatment of SCLC.
- Author
-
Andrini E, Ricco G, Zappi A, Aloi S, Giordano M, Altimari A, Gruppioni E, Maloberti T, de Biase D, Campana D, and Lamberti G
- Subjects
- Humans, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Temozolomide therapeutic use, Lung Neoplasms drug therapy, Small Cell Lung Carcinoma drug therapy, Small Cell Lung Carcinoma pathology, Antineoplastic Agents, Alkylating therapeutic use
- Abstract
Small-cell lung cancer (SCLC), accounting for 10-20 % of all lung tumors, represents the most aggressive high-grade neuroendocrine carcinoma. Most patients are diagnosed with extensive-stage SCLC (ES-SCLC), with brian metastases identified in ∼ 80 % of cases during the disease cours, and the prognosis is dismal, with a 5-year survival rate of less than 5 %. Current available treatments in the second-line setting are limited, and topotecan has long been the only FDA-approved drug in relapsed or refractory ES-SCLC, until the recent approval of lurbinectedin, a selective inhibitor of RNA polymerase II. Temozolomide (TMZ) is an oral alkylating agent, which showed single-agent activity in SCLC, particularly among patients with O
6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation. Several studies have revealed the synergistic activity of temozolomide with poly-ADP-ribose polymerase (PARP) inhibitors, that prevent repair of TMZ-induced DNA damage. This review focuses on the rationale for the use of TMZ in ES-SCLC and provides an overview of the main trials that have evaluated and are currently investigating its role, both as a single-agent and in combinations, in relapse or refractory disease., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
14. Imaging of Neuroendocrine Neoplasms; Principles of Treatment Strategies. What Referring Clinicians Want to Know.
- Author
-
Asmundo L, Ambrosini V, Mojtahed A, Fanti S, Ferrone C, Hesami M, Sertic M, Najmi Z, Furtado FS, Dhami RS, Anderson MA, Samir A, Sharma A, Campana D, Ursprung S, Nikolau K, Domachevsky L, Blake MA, Norris EC, Clark JW, and Catalano OA
- Subjects
- Humans, Diagnostic Imaging methods, Referral and Consultation, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors therapy
- Abstract
Abstract: Neuroendocrine neoplasms (NENs) are a diverse group of tumors that express neuroendocrine markers and primarily affect the lungs and digestive system. The incidence of NENs has increased over time due to advancements in imaging and diagnostic techniques. Effective management of NENs requires a multidisciplinary approach, considering factors such as tumor location, grade, stage, symptoms, and imaging findings. Treatment strategies vary depending on the specific subtype of NEN. In this review, we will focus on treatment strategies and therapies including the information relevant to clinicians in order to undertake optimal management and treatment decisions, the implications of different therapies on imaging, and how to ascertain their possible complications and treatment effects., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach.
- Author
-
Asmundo L, Ambrosini V, Anderson MA, Fanti S, Bradley WR, Campana D, Mojtahed A, Chung R, Mcdermott S, Digumarthy S, Ursprung S, Nikolau K, Fintelmann FJ, Blake M, Fernandez-Del Castillo C, Qadan M, Pandey A, Clark JW, and Catalano OA
- Subjects
- Humans, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors therapy, Neuroendocrine Tumors pathology
- Abstract
Abstract: Neuroendocrine neoplasms (NENs) are rare neoplasms originating from neuroendocrine cells, with increasing incidence due to enhanced detection methods. These tumors display considerable heterogeneity, necessitating diverse management strategies based on factors like organ of origin and tumor size. This article provides a comprehensive overview of therapeutic approaches for NENs, emphasizing the role of imaging in treatment decisions. It categorizes tumors based on their locations: gastric, duodenal, pancreatic, small bowel, colonic, rectal, appendiceal, gallbladder, prostate, lung, gynecological, and others. The piece also elucidates the challenges in managing metastatic disease and controversies surrounding MEN1-neuroendocrine tumor management. The article underscores the significance of individualized treatment plans, underscoring the need for a multidisciplinary approach to ensure optimal patient outcomes., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. [Appendix ... it's not just appendicitis: neuroendocrine tumors.]
- Author
-
Mainetti M, Aprile MR, Campana D, and Marchetti F
- Subjects
- Adolescent, Humans, Colectomy methods, Appendectomy methods, Appendiceal Neoplasms pathology, Appendiceal Neoplasms diagnosis, Appendiceal Neoplasms surgery, Appendicitis surgery, Appendicitis diagnosis, Appendicitis pathology, Neuroendocrine Tumors pathology, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors surgery
- Abstract
Well-differentiated neuroendocrine tumors of the appendix (NETs) are rare in pediatric and adolescent age groups. However, they are the most common gastrointestinal epithelial tumor in this age group and the most common malignancy of the appendix in the general population. The classification of these tumors considers factors such as the proliferation index, size of the neoplasm, and the presence of perineural and/or lymphovascular invasion, which can contribute to distant metastases. Preoperative diagnosis is challenging, except in cases where patients exhibit symptoms of carcinoid syndrome or signs of metastatic disease, which are uncommon in pediatric and adolescent patients. For tumors smaller than 1 cm, appendectomy is usually curative, while larger tumors or those at risk of spreading may require right hemicolectomy with lymphadenectomy. We present a case of an adolescent with NET and provide a literature review on the diagnostic and therapeutic approaches that should be considered for this relatively rare condition.Key words. Adolescent age, appendix, neuroendocrine tumors, pediatric age.
- Published
- 2024
- Full Text
- View/download PDF
17. β1600 Q.Clear Digital Reconstruction of [ 68 Ga]Ga-DOTANOC PET/CT Improves Image Quality in NET Patients.
- Author
-
Di Franco M, Fortunati E, Zanoni L, Bonazzi N, Mosconi C, Malizia C, Civollani S, Campana D, Andrini E, Lamberti G, Allegri V, Fanti S, and Ambrosini V
- Abstract
Background: Image reconstruction is crucial for improving overall image quality and diagnostic accuracy. Q.Clear is a novel reconstruction algorithm that reduces image noise. The aim of the present study is to assess the preferred Q.Clear β-level for digital [
68 Ga]Ga-DOTANOC PET/CT reconstruction vs. standard reconstruction (STD) for both overall scan and single-lesion visualization. Methods: Inclusion criteria: (1) patients with/suspected neuroendocrine tumors included in a prospective observational monocentric study between September 2019 and January 2022; (2) [68 Ga]Ga-DOTANOC digital PET/CT and contrast-enhanced-CT (ceCT) performed at our center at the same time. Images were reconstructed with STD and with Q.Clear β-levels 800, 1000, and 1600. Scans were blindly reviewed by three nuclear-medicine experts: the preferred β-level reconstruction was independently chosen for the visual quality of both the overall scan and the most avid target lesion < 1 cm (t) and >1 cm (T). PET/CT results were compared to ceCT. Semiquantitative analysis was performed (STD vs. β1600) in T and t concordant at both PET/CT and ceCT. Subgroup analysis was also performed in patients presenting discordant t. Results : Overall, 52 patients were included. β1600 reconstruction was considered superior over the others for both overall scan quality and single-lesion detection in all cases. The only significantly different ( p < 0.001) parameters between β1600 and STD were signal-to-noise liver ratio and standard deviation of the liver background. Lesion-dependent parameters were not significantly different in concordant T ( n = 37) and t ( n = 10). Among 26 discordant t, when PET was positive, all findings were confirmed as malignant. Conclusions : β1600 Q.Clear reconstruction for [68 Ga]Ga-DOTANOC imaging is feasible and improves image quality for both overall and small-lesion assessment.- Published
- 2024
- Full Text
- View/download PDF
18. Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia.
- Author
-
Oh BLZ, Vinanica N, Wong DMH, and Campana D
- Subjects
- Humans, T-Lymphocytes immunology, T-Lymphocytes metabolism, T-Lymphocytes transplantation, Animals, Treatment Outcome, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell immunology, Receptors, Chimeric Antigen immunology, Immunotherapy, Adoptive methods, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma therapy, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma immunology
- Abstract
Chimeric antigen receptor (CAR) T-cell therapy is a new and effective treatment for patients with hematologic malignancies. Clinical responses to CAR T cells in leukemia, lymphoma, and multiple myeloma have provided strong evidence of the antitumor activity of these cells. In patients with refractory or relapsed B-cell acute lymphoblastic leukemia (ALL), the infusion of autologous anti-CD19 CAR T cells is rapidly gaining standard-of-care status and might eventually be incorporated into frontline treatment. In T-ALL, however, leukemic cells generally lack surface molecules recognized by established CAR, such as CD19 and CD22. Such deficiency is particularly important, as outcome is dismal for patients with T-ALL that is refractory to standard chemotherapy and/or hematopoietic stem cell transplant. Recently, CAR T-cell technologies directed against T-cell malignancies have been developed and are beginning to be tested clinically. The main technical obstacles stem from the fact that malignant and normal T cells share most surface antigens. Therefore, CAR T cells directed against T-ALL targets might be susceptible to self-elimination during manufacturing and/or have suboptimal activity after infusion. Moreover, removing leukemic cells that might be present in the cell source used for CAR T-cell manufacturing might be problematic. Finally, reconstitution of T cells and natural killer cells after CAR T-cell infusion might be impaired. In this article, we discuss potential targets for CAR T-cell therapy of T-ALL with an emphasis on CD7, and review CAR configurations as well as early clinical results.
- Published
- 2024
- Full Text
- View/download PDF
19. Clinical Outcome of Patients with Gastric, Duodenal, or Rectal Neuroendocrine Tumors after Incomplete Endoscopic Resection.
- Author
-
Dell'Unto E, Marasco M, Mosca M, Gallo C, Esposito G, Rinzivillo M, Pilozzi E, Orrù F, Campana D, Massironi S, Annibale B, and Panzuto F
- Abstract
Objectives: Our aim was to investigate the clinical outcome of patients with well-differentiated gastric, duodenal, and rectal neuroendocrine tumors after treatment with incomplete endoscopic resection due to the finding of microscopic positive resection margins (R1). Methods: This is a retrospective analysis of consecutive patients with type 1 gastric, non-ampullary non-functioning duodenal, or rectal neuroendocrine neoplasms with positive R1 margins after endoscopic resection. The rate of tumor recurrence and progression-free survival were considered to be the study's main endpoints. Statistical analysis was performed using MedCalc
® v.17 software and a p -value of <0.05 was considered significant. A Cox proportional-hazard regression was performed to identify risk factors for disease recurrence/progression. Results: After evaluating 110 patients, a total of 58 patients were included in the final analysis (15 gastric NENs, 12 duodenal NENs, and 31 rectal NENs). After evidence of endoscopic R1 resection had been gathered, 26 patients (44.8%) underwent an endoscopic/surgical extension of the previous resection. Tumor progression (all local recurrences) occurred in five out of fifty-eight patients (8.6%) with a median PFS of 36 months. There were no tumor-related deaths. G2 grading and the gastric primary tumor site were the only features significantly associated with the risk of recurrence of the disease (HR: 11.97 [95% CI: 1.22-116.99], HR: 12.54 [95% CI: 1.28-122.24], respectively). Conclusions: Tumor progression rarely occurs in patients with microscopic positive margin excision (R1) after endoscopic resection and does not seem to affect patients' clinical outcomes.- Published
- 2024
- Full Text
- View/download PDF
20. Gastric neuroendocrine neoplasms.
- Author
-
Lamberti G, Panzuto F, Pavel M, O'Toole D, Ambrosini V, Falconi M, Garcia-Carbonero R, Riechelmann RP, Rindi G, and Campana D
- Subjects
- Humans, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors epidemiology, Neuroendocrine Tumors therapy, Zollinger-Ellison Syndrome complications, Gastritis, Atrophic complications, Gastritis, Atrophic epidemiology, Stomach Neoplasms diagnosis, Stomach Neoplasms epidemiology, Stomach Neoplasms therapy, Pancreatic Neoplasms
- Abstract
Gastric neuroendocrine neoplasms (gNENs) display peculiar site-specific features among all NENs. Their incidence and prevalence have been rising in the past few decades. gNENs comprise gastric neuroendocrine carcinomas (gNECs) and gastric neuroendocrine tumours (gNETs), the latter further classified into three types. Type I anatype II gNETs are gastrin-dependent and develop in chronic atrophic gastritis and as part of Zollinger-Ellison syndrome within a multiple endocrine neoplasia type 1 syndrome (MEN1), respectively. Type III or sporadic gNETs develop in the absence of hypergastrinaemia and in the context of a near-normal or inflamed gastric mucosa. gNECs can also develop in the context of variable atrophic, relatively normal or inflamed gastric mucosa. Each gNEN type has different clinical characteristics and requires a different multidisciplinary approach in expert dedicated centres. Type I gNETs are managed mainly by endoscopy or surgery, whereas the treatment of type II gNETs largely depends on the management of the concomitant MEN1. Type III gNETs may require both locoregional approaches and systemic treatments; NECs are often metastatic and therefore require systemic treatment. Specific data regarding the systemic treatment of gNENs are lacking and are derived from the treatment of intestinal NETs and NECs. An enhanced understanding of molecular and clinical pathophysiology is needed to improve the management and outcomes of patients' gNETs., (© 2024. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
21. Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort.
- Author
-
Panzuto F, Andrini E, Lamberti G, Pusceddu S, Rinzivillo M, Gelsomino F, Raimondi A, Bongiovanni A, Davì MV, Cives M, Brizzi MP, Persano I, Zatelli MC, Puliafito I, Tafuto S, and Campana D
- Abstract
Background: The optimal treatment sequencing for advanced, well-differentiated pancreatic neuroendocrine tumors (pNETs) is unknown. We performed a multicenter, retrospective study to evaluate the best treatment sequence in terms of progression-free survival to first-line (PFS1) and to second-line (PFS2), and overall survival among patients with advanced, well-differentiated pNETs. Methods : This multicenter study retrospectively analyzed the prospectively collected data of patients with sporadic well-differentiated pNETs who received at least two consecutive therapeutic lines, with evidence of radiological disease progression before change of treatment lines. Results : Among 201 patients, 40 (19.9%) had a grade 1 and 149 (74.1%) a grade 2 pNET. Primary tumor resection was performed in 98 patients (48.8%). First-line therapy was performed in 128 patients with somatostatin analogs (SSA), 35 received SSA + radioligand therapy (RLT), 21 temozolomide-based chemotherapy, and 17 SSA + targeted therapy. PFS was significantly longer in patients with grade 1 pNETs compared to those with grade 2, in patients who received primary tumor surgery, and in patients treated with RLT compared to other treatments. At multivariate analysis, the use of upfront RLT was independently associated with improved PFS compared to SSA. Second-line therapy was performed in 94 patients with SSA + targeted therapy, 35 received chemotherapy, 45 SSA + RLT, and 27 nonconventional-dose SSA or SSA switch. PFS was significantly longer in patients treated with RLT compared to other treatments. At multivariate analysis, the type of second-line therapy was independently associated with the risk for progression. OS was significantly longer in patients who received primary tumor surgery, with Ki67 < 10%, without extrahepatic disease, and in patients who received SSA-RLT sequence compared to other sequences. Conclusions : In this large, multicenter study, RLT was associated with better PFS compared to other treatments, and the SSA-RLT sequence was associated with the best survival outcomes in patients with pNETs with Ki67 < 10%. Primary tumor surgery was also associated with improved survival.
- Published
- 2024
- Full Text
- View/download PDF
22. Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database.
- Author
-
Panzuto F, Partelli S, Campana D, de Braud F, Spada F, Cives M, Tafuto S, Bertuzzi A, Gelsomino F, Bergamo F, Marcucci S, Mastrangelo L, Massironi S, Appetecchia M, Filice A, Badalamenti G, Bartolomei M, Amoroso V, Landoni L, Rodriquenz MG, Valente M, Colao A, Isidori A, Fanciulli G, Bollina R, Ciola M, Butturini G, Marconcini R, Arvat E, Cinieri S, Berardi R, Baldari S, Riccardi F, Spoto C, Giuffrida D, Gattuso D, Ferone D, Rinzivillo M, Bertani E, Versari A, Zerbi A, Lamberti G, Lauricella E, Pusceddu S, Fazio N, Dell'Unto E, Marini M, and Falconi M
- Subjects
- Humans, Italy epidemiology, Multicenter Studies as Topic, Observational Studies as Topic, Prognosis, Registries, Routinely Collected Health Data, Gastrointestinal Neoplasms pathology, Intestinal Neoplasms diagnosis, Intestinal Neoplasms epidemiology, Intestinal Neoplasms therapy, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors epidemiology, Neuroendocrine Tumors therapy, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms therapy, Stomach Neoplasms diagnosis, Stomach Neoplasms epidemiology, Stomach Neoplasms therapy
- Abstract
Neuroendocrine neoplasms (NENs) are rare tumors with diverse clinical behaviors. Large databases like the Surveillance, Epidemiology, and End Results (SEER) program and national NEN registries have provided significant epidemiological knowledge, but they have limitations given the recent advancements in NEN diagnostics and treatments. For instance, newer imaging techniques and therapies have revolutionized NEN management, rendering older data less representative. Additionally, crucial parameters, like the Ki67 index, are missing from many databases. Acknowledging these gaps, the Italian Association for Neuroendocrine Tumors (Itanet) initiated a national multicenter prospective database in 2019, aiming to gather data on newly-diagnosed gastroenteropancreatic neuroendocrine (GEP) NENs. This observational study, coordinated by Itanet, includes patients from 37 Italian centers. The database, which is rigorously maintained and updated, focuses on diverse parameters including age, diagnostic techniques, tumor stage, treatments, and survival metrics. As of October 2023, data from 1,600 patients have been recorded, with an anticipation of reaching 3600 by the end of 2025. This study aims at understanding the epidemiology, clinical attributes, and treatment strategies for GEP-NENs in Italy, and to introduce the Itanet database project. Once comprehensive follow-up data will be acquired, the goal will be to discern predictors of treatment outcomes and disease prognosis. The Itanet database will offer an unparalleled, updated perspective on GEP-NENs, addressing the limitations of older databases and aiding in optimizing patient care. STUDY REGISTRATION: This protocol was registered in clinicaltriasl.gov (NCT04282083)., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
23. Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis.
- Author
-
Khoury T, Sbeit W, Fusaroli P, Campana D, Brighi N, Napoleon B, and Lisotti A
- Subjects
- Humans, Treatment Outcome, Ultrasonography, Interventional, Endosonography, Neuroendocrine Tumors surgery, Neuroendocrine Tumors diagnostic imaging, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms surgery, Radiofrequency Ablation methods, Radiofrequency Ablation standards
- Abstract
Objective: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has been constantly increasing, particularly in the treatment of pancreatic neuroendocrine neoplasms (pNENs). While emerging data in this field are accumulating, we aimed to assess the pooled efficacy and safety of EUS-RFA for pNENs., Methods: The PubMed/Medline, Embase, and Cochrane Library databases search was conducted to identify studies reporting EUS-RFA of pNENs with outcomes of interest (efficacy and safety). The primary outcome was radiological response. Efficacy was assessed by the pooled clinical response rate, whereas safety was assessed by the pooled adverse events (AEs) rate. Heterogeneity was assessed using I
2 . Pooled estimates and the 95% confidence interval (CI) were calculated using a random-effect model., Results: Eleven studies involving 292 patients were included. The pooled technical success rate was 99.2% (95% CI 97.9-99.9%), with no heterogeneity. The pooled complete radiological response was 87.1% (95% CI 80.1-92.8%). The pooled partial response was 11.4% (95% CI 6.2-18.1%). The pooled clinical response rate for functional pNENs was 94.9% (95% CI 90.7-97.9%), with no heterogeneity. The pooled incidence of AEs was 20.0% (95% CI 14.0-26.7%); most AEs were mild to moderate in grade, while the pooled incidence of severe AEs was 0.9% (95% CI 0.2-2.3%). The most common AEs were transient mild abdominal pain in 19 patients (6.5%), and mild to moderate pancreatitis in 23 patients (7.9%). No cases of mortality were reported., Conclusion: Endoscopic ultrasound-guided radiofrequency ablation resulted on a feasible approach for pNENs treatment, with excellent technical success, high radiological and clinical response, and acceptable AE rate., (© 2023 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.)- Published
- 2024
- Full Text
- View/download PDF
24. Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients.
- Author
-
Bonazzi N, Fortunati E, Zanoni L, Argalia G, Calabrò D, Tabacchi E, Allegri V, Campana D, Andrini E, Lamberti G, Di Franco M, Casadei R, Ricci C, Mosconi C, Fanti S, and Ambrosini V
- Abstract
The recent introduction of novel treatments for advanced neuroendocrine tumors (NETs) and the well-established impact of clinical case discussion within dedicated multidisciplinary teams indicates the need to promote the centralization of rare diseases, such as NENs (neuroendocrine neoplasms). Data on the real-life use of and indications for [68Ga]Ga-DOTANOC PET/CT were collected from a prospective monocentric 5-year electronic archive including consecutive patients with confirmed and suspected NETs (September 2017 to May 2022). Overall, 2082 [68Ga]Ga-DOTANOC PET/CT scans (1685 confirmed NETs, 397 suspected NETs) were performed in 1537 patients. A high positivity rate was observed across different clinical settings (approximately 70%). Approximately 910/2082 scans were requested by the local oncology ward (851 confirmed NETs, 59 suspected NETs). The following observations were found: (i) the detection rate across all indications was 73.2% (higher for staging, peptide receptor radioligand therapy (PRRT) selection, and treatment response assessment); (ii) in suspected NETs, PET was more often positive when based on radiological findings. This systematic data collection in a high-volume diagnostic center represents a reliable cohort reflecting the global trends in the use of [68Ga]Ga-DOTANOC PET/CT for different clinical indications and primary tumor sites, but prompts the need for further multicenter data sharing in such a rare and slowly progressive disease setting.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.